Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.74
LGND's Cash-to-Debt is ranked lower than
84% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. LGND: 0.74 )
Ranked among companies with meaningful Cash-to-Debt only.
LGND' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.51 Max: No Debt
Current: 0.74
Equity-to-Asset 0.59
LGND's Equity-to-Asset is ranked lower than
59% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. LGND: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
LGND' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.83  Med: 0.15 Max: 0.83
Current: 0.59
-0.83
0.83
Interest Coverage 3.22
LGND's Interest Coverage is ranked lower than
94% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. LGND: 3.22 )
Ranked among companies with meaningful Interest Coverage only.
LGND' s Interest Coverage Range Over the Past 10 Years
Min: 0.06  Med: 3.82 Max: No Debt
Current: 3.22
Piotroski F-Score: 4
Altman Z-Score: 5.30
Beneish M-Score: -3.17
WACC vs ROIC
9.21%
1.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 35.92
LGND's Operating Margin % is ranked higher than
94% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. LGND: 35.92 )
Ranked among companies with meaningful Operating Margin % only.
LGND' s Operating Margin % Range Over the Past 10 Years
Min: -466.69  Med: -6.83 Max: 40.27
Current: 35.92
-466.69
40.27
Net Margin % -2.92
LGND's Net Margin % is ranked higher than
68% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. LGND: -2.92 )
Ranked among companies with meaningful Net Margin % only.
LGND' s Net Margin % Range Over the Past 10 Years
Min: -359.19  Med: 8.57 Max: 2184.64
Current: -2.92
-359.19
2184.64
ROE % -0.86
LGND's ROE % is ranked higher than
75% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. LGND: -0.86 )
Ranked among companies with meaningful ROE % only.
LGND' s ROE % Range Over the Past 10 Years
Min: -1046.55  Med: 30.84 Max: 997.71
Current: -0.86
-1046.55
997.71
ROA % -0.52
LGND's ROA % is ranked higher than
76% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. LGND: -0.52 )
Ranked among companies with meaningful ROA % only.
LGND' s ROA % Range Over the Past 10 Years
Min: -56.92  Med: 3.17 Max: 112.83
Current: -0.52
-56.92
112.83
ROC (Joel Greenblatt) % 564.68
LGND's ROC (Joel Greenblatt) % is ranked higher than
98% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. LGND: 564.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LGND' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1252.88  Med: -29.29 Max: 6370.4
Current: 564.68
-1252.88
6370.4
3-Year Revenue Growth Rate 30.40
LGND's 3-Year Revenue Growth Rate is ranked higher than
80% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. LGND: 30.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LGND' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -65  Med: 8.05 Max: 91
Current: 30.4
-65
91
3-Year EBITDA Growth Rate 46.10
LGND's 3-Year EBITDA Growth Rate is ranked higher than
87% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. LGND: 46.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LGND' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -76.7  Med: -10.3 Max: 112.5
Current: 46.1
-76.7
112.5
GuruFocus has detected 4 Warning Signs with Ligand Pharmaceuticals Inc $LGND.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LGND's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:ABCZF, NYSE:AXON, NAS:RARE, NAS:AGIO, NAS:TBPH, NAS:FGEN, NAS:PRTA, NAS:AVXS, NAS:CBPO, NYSE:XON, NAS:JUNO, NAS:HALO, NAS:NKTR, NAS:LOXO, NAS:SAGE, OTCPK:MPSYY, NAS:PTLA, NYSE:CBM, NAS:PBYI, NAS:BPMC » details
Traded in other countries:LGDN.Germany,
Headquarter Location:USA
Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.

Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Ratios

vs
industry
vs
history
Forward PE Ratio 49.26
LGND's Forward PE Ratio is ranked lower than
81% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 22.68 vs. LGND: 49.26 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 222.79
LGND's Price-to-Owner-Earnings is ranked lower than
95% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.51 vs. LGND: 222.79 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LGND' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.5  Med: 123.32 Max: 1729.23
Current: 222.79
1.5
1729.23
PB Ratio 7.00
LGND's PB Ratio is ranked lower than
73% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. LGND: 7.00 )
Ranked among companies with meaningful PB Ratio only.
LGND' s PB Ratio Range Over the Past 10 Years
Min: 5.26  Med: 19.86 Max: 174.72
Current: 7
5.26
174.72
PS Ratio 24.90
LGND's PS Ratio is ranked lower than
68% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. LGND: 24.90 )
Ranked among companies with meaningful PS Ratio only.
LGND' s PS Ratio Range Over the Past 10 Years
Min: 4.63  Med: 18.11 Max: 714.32
Current: 24.9
4.63
714.32
Price-to-Free-Cash-Flow 50.93
LGND's Price-to-Free-Cash-Flow is ranked lower than
72% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 28.96 vs. LGND: 50.93 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LGND' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 42.62  Med: 67.78 Max: 305.2
Current: 50.93
42.62
305.2
Price-to-Operating-Cash-Flow 36.88
LGND's Price-to-Operating-Cash-Flow is ranked lower than
68% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 25.50 vs. LGND: 36.88 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LGND' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 30.86  Med: 59.91 Max: 3653.33
Current: 36.88
30.86
3653.33
EV-to-EBIT 68.12
LGND's EV-to-EBIT is ranked lower than
85% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.27 vs. LGND: 68.12 )
Ranked among companies with meaningful EV-to-EBIT only.
LGND' s EV-to-EBIT Range Over the Past 10 Years
Min: -933.3  Med: -3.5 Max: 553.2
Current: 68.12
-933.3
553.2
EV-to-EBITDA 52.41
LGND's EV-to-EBITDA is ranked lower than
84% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 18.63 vs. LGND: 52.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
LGND' s EV-to-EBITDA Range Over the Past 10 Years
Min: -227.8  Med: 39.55 Max: 823.2
Current: 52.41
-227.8
823.2
Shiller PE Ratio 214.47
LGND's Shiller PE Ratio is ranked lower than
90% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.27 vs. LGND: 214.47 )
Ranked among companies with meaningful Shiller PE Ratio only.
LGND' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.8  Med: 74.89 Max: 452.47
Current: 214.47
23.8
452.47
Current Ratio 0.77
LGND's Current Ratio is ranked lower than
91% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. LGND: 0.77 )
Ranked among companies with meaningful Current Ratio only.
LGND' s Current Ratio Range Over the Past 10 Years
Min: 0.28  Med: 1.75 Max: 12.94
Current: 0.77
0.28
12.94
Quick Ratio 0.74
LGND's Quick Ratio is ranked lower than
89% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. LGND: 0.74 )
Ranked among companies with meaningful Quick Ratio only.
LGND' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 1.65 Max: 12.87
Current: 0.74
0.26
12.87
Days Inventory 282.22
LGND's Days Inventory is ranked lower than
84% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 131.03 vs. LGND: 282.22 )
Ranked among companies with meaningful Days Inventory only.
LGND' s Days Inventory Range Over the Past 10 Years
Min: 33.18  Med: 79.07 Max: 282.22
Current: 282.22
33.18
282.22
Days Sales Outstanding 23.72
LGND's Days Sales Outstanding is ranked higher than
82% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. LGND: 23.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
LGND' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.79  Med: 49.24 Max: 146.43
Current: 23.72
5.79
146.43
Days Payable 475.38
LGND's Days Payable is ranked higher than
94% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 54.41 vs. LGND: 475.38 )
Ranked among companies with meaningful Days Payable only.
LGND' s Days Payable Range Over the Past 10 Years
Min: 179.13  Med: 282.1 Max: 822.72
Current: 475.38
179.13
822.72

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.70
LGND's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. LGND: -0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LGND' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -36.5  Med: -8.15 Max: 0.3
Current: -0.7
-36.5
0.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 36.12
LGND's Price-to-Tangible-Book is ranked lower than
96% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. LGND: 36.12 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LGND' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.83  Med: 18.78 Max: 206.67
Current: 36.12
4.83
206.67
Price-to-Intrinsic-Value-Projected-FCF 4.42
LGND's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
61% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 3.46 vs. LGND: 4.42 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LGND' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 3.78  Med: 5.13 Max: 40.37
Current: 4.42
3.78
40.37
Price-to-Median-PS-Value 1.38
LGND's Price-to-Median-PS-Value is ranked lower than
72% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. LGND: 1.38 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LGND' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.66 Max: 35.16
Current: 1.38
0.2
35.16
Earnings Yield (Greenblatt) % 1.47
LGND's Earnings Yield (Greenblatt) % is ranked higher than
78% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. LGND: 1.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LGND' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -59.1  Med: -0.9 Max: 2
Current: 1.47
-59.1
2

More Statistics

Revenue (TTM) (Mil) $108.59
EPS (TTM) $ -0.18
Beta1.06
Short Percentage of Float29.17%
52-Week Range $87.50 - 139.79
Shares Outstanding (Mil)21.00

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 134 187 231
EPS ($) 2.52 3.80 4.90
EPS without NRI ($) 2.52 3.80 4.90
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for LGND

Headlines

Articles On GuruFocus.com
Gurus Invest in Top Biotechnology Stocks Jun 20 2016 
RS Investment Increases Holdings in Ulta Salon, Noble Energy and Fortune Brands Dec 23 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 

More From Other Websites
Ligand Gets Milestone Payment on Partner Drug FDA Approval Jun 21 2017
Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for... Jun 20 2017
Why Is Ligand Pharmaceuticals (LGND) Up 5.1% Since the Last Earnings Report? Jun 13 2017
Key FDA Events to Watch Out for in Jun 2017 Jun 05 2017
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Surface Oncology Jun 01 2017
Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : June... Jun 01 2017
Ligand Announces Aziyo Biologics Acquires Commercial Products from Partner CorMatrix May 31 2017
Ligand (LGND) Signs Licensing Deal with xCella Biosciences May 31 2017
Ligand Enters Into Worldwide OmniAb® Platform License Agreement With xCella Biosciences May 30 2017
ETFs with exposure to Ligand Pharmaceuticals, Inc. : May 22, 2017 May 22 2017
Ligand to Participate in Two Upcoming Investor Conferences May 22 2017
Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 May 19 2017
Edited Transcript of LGND earnings conference call or presentation 9-May-17 8:30pm GMT May 15 2017
These 3 Stocks Look Expensive but Are Actually Cheap May 11 2017
Ligand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates May 10 2017
Ligand posts 1Q profit May 09 2017
Ligand Reports First Quarter 2017 Financial Results May 09 2017
Investor Network: Ligand Pharmaceuticals Incorporated to Host Earnings Call May 09 2017
Can Ligand (LGND) Spring a Surprise this Earnings Season? May 04 2017
Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : April 27, 2017 Apr 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}